Cholecalciferol for the Prophylaxis Against Recurrent Urinary Tract Infection Among Patients with Benign Prostatic Hyperplasia: a Randomized, Comparative Study

Overview

Journal World J Urol

Specialty Urology

Date 2018 Oct 27

PMID 30361957

Citations 4

Authors

Ahmed S Safwat

Ahmad Hasanain

Ahmed Shahat

Mostafa AbdelRazek

Hazem Orabi

Samir K Abdul Hamid

Amany Nafee

Sally Bakkar

Mohamed Sayed

Affiliations

Soon will be listed here.

Abstract

Purpose: To explore the role of cholecalciferol for the prophylaxis against recurrent urinary tract infection (UTI) in patients with benign prostatic hyperplasia (BPH).

Methods: Our randomized, uncontrolled prospective study included 389 naïve BPH patients with moderate/severe symptoms, consecutively. The patients were randomly allocated to two groups; group-A included 193 patients who received tamsulosin, while group-B included another 196 patients who received tamsulosin with cholecalciferol. The study population was followed up for 2 years after the start of the treatment. For all the patients enrolled, clinical evaluation, imaging studies (abdominal and trans-rectal ultrasonography), and laboratory investigations [including urinalysis, urine culture with antibiotic susceptibility testing for positive cultures and estimation of prostate-specific antigen (PSA) level] were provided.

Results: The incidence rate of recurrent UTI was 9% among the study population; it was significantly higher among group-A patients compared to those of group-B (13.5% vs. 4.6%, p 0.003, OR 2.7, 95% CI 1.5-4.3). Compared to patients of group-A, those of group-B developed a significantly lower level of PSA at the end of treatment period (0.16 ± 0.03 ng/mL vs. 0.27 ± 0.08 ng/mL, p 0.043, OR 1.9, 95% CI 1.2-6.8).

Conclusions: Adjuvant cholecalciferol supplementation may be protective against recurrent UTI among patients with BPH receiving tamsulosin therapy without extra adverse effects.

Citing Articles

Genetic Predisposition to Benign Prostatic Hyperplasia: Where Do We Stand?.

Hennenberg M, Hu S, Tamalunas A, Stief C Eur Urol Open Sci. 2024; 70:154-157.

PMID: 39554302 PMC: 11563937. DOI: 10.1016/j.euros.2024.10.012.

Definitions of Urinary Tract Infection in Current Research: A Systematic Review.

Bilsen M, Jongeneel R, Schneeberger C, Platteel T, Van Nieuwkoop C, Mody L Open Forum Infect Dis. 2023; 10(7):ofad332.

PMID: 37426954 PMC: 10323732. DOI: 10.1093/ofid/ofad332.

The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and....

Sakalis V, Gkotsi A, Charpidou D, Tsafrakidis P, Apostolidis A Cent European J Urol. 2021; 74(3):388-421.

PMID: 34729231 PMC: 8552938. DOI: 10.5173/ceju.2021.132.R1.

Dietary Factors and Supplements Influencing Prostate Specific-Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials.

Grammatikopoulou M, Gkiouras K, Papageorgiou S, Myrogiannis I, Mykoniatis I, Papamitsou T Nutrients. 2020; 12(10).

PMID: 33003518 PMC: 7600271. DOI: 10.3390/nu12102985.

References

Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T . Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int. 1999; 84(4):470-4. DOI: 10.1046/j.1464-410x.1999.00164.x. View

Murthy S, Agoulnik I, Weigel N . Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005; 64(4):362-72. DOI: 10.1002/pros.20251. View

Adorini L . Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol. 2005; 233(2):115-24. DOI: 10.1016/j.cellimm.2005.04.013. View

Gombart A, Borregaard N, Koeffler H . Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005; 19(9):1067-77. DOI: 10.1096/fj.04-3284com. View

Colli E, Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N . BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2005; 49(1):82-6. DOI: 10.1016/j.eururo.2005.08.014. View

Yee S, Campbell M, Simons C . Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol. 2006; 98(4-5):228-35. DOI: 10.1016/j.jsbmb.2005.11.004. View

Chromek M, Slamova Z, Bergman P, Kovacs L, Podracka L, Ehren I . The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med. 2006; 12(6):636-41. DOI: 10.1038/nm1407. View

Norman A . Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology. 2006; 147(12):5542-8. DOI: 10.1210/en.2006-0946. View

Kristal A, Arnold K, Schenk J, Neuhouser M, Goodman P, Penson D . Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008; 167(8):925-34. DOI: 10.1093/aje/kwm389. View

10.

White J . Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun. 2008; 76(9):3837-43. PMC: 2519414. DOI: 10.1128/IAI.00353-08. View

11.

Bikle D . Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens. 2008; 17(4):348-52. DOI: 10.1097/MNH.0b013e3282ff64a3. View

12.

Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E . The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2008; 69(5):480-93. DOI: 10.1002/pros.20896. View

13.

Pourmand G, Abedi A, Karami A, Khashayar P, Mehrsai A . Urinary infection before and after prostatectomy. Saudi J Kidney Dis Transpl. 2010; 21(2):290-4. View

14.

Badalian S, Rosenbaum P . Vitamin D and pelvic floor disorders in women: results from the National Health and Nutrition Examination Survey. Obstet Gynecol. 2010; 115(4):795-803. DOI: 10.1097/AOG.0b013e3181d34806. View

15.

Adorini L, Penna G, Fibbi B, Maggi M . Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann N Y Acad Sci. 2010; 1193:146-52. DOI: 10.1111/j.1749-6632.2009.05299.x. View

16.

Juzeniene A, Ma L, Kwitniewski M, Polev G, Lagunova Z, Dahlback A . The seasonality of pandemic and non-pandemic influenzas: the roles of solar radiation and vitamin D. Int J Infect Dis. 2010; 14(12):e1099-105. DOI: 10.1016/j.ijid.2010.09.002. View

17.

van der Starre W, Van Nieuwkoop C, Paltansing S, Vant Wout J, Groeneveld G, Becker M . Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother. 2010; 66(3):650-6. DOI: 10.1093/jac/dkq465. View

18.

Hertting O, Holm A, Luthje P, Brauner H, Dyrdak R, Jonasson A . Vitamin D induction of the human antimicrobial Peptide cathelicidin in the urinary bladder. PLoS One. 2010; 5(12):e15580. PMC: 3001888. DOI: 10.1371/journal.pone.0015580. View

19.

Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R . Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(7):1911-30. DOI: 10.1210/jc.2011-0385. View

20.

Espinosa G, Esposito R, Kazzazi A, Djavan B . Vitamin D and benign prostatic hyperplasia -- a review. Can J Urol. 2013; 20(4):6820-5. View